Literature DB >> 22158418

Chk2 mediates RITA-induced apoptosis.

J de Lange1, M Verlaan-de Vries, A F A S Teunisse, A G Jochemsen.   

Abstract

Reactivation of the p53 tumor-suppressor protein by small molecules like Nutlin-3 and RITA (reactivation of p53 and induction of tumor cell apoptosis) is a promising strategy for cancer therapy. The molecular mechanisms involved in the responses to RITA remain enigmatic. Several groups reported the induction of a p53-dependent DNA damage response. Furthermore, the existence of a p53-dependent S-phase checkpoint has been suggested, involving the checkpoint kinase Chk1. We have recently shown synergistic induction of apoptosis by RITA in combination with Nutlin-3, and we observed concomitant Chk2 phosphorylation. Therefore, we investigated whether Chk2 contributes to the cellular responses to RITA. Strikingly, the induction of apoptosis seemed entirely Chk2 dependent. Transcriptional activity of p53 in response to RITA required the presence of Chk2. A partial rescue of apoptosis observed in Noxa knockdown cells emphasized the relevance of p53 transcriptional activity for RITA-induced apoptosis. In addition, we observed an early p53- and Chk2-dependent block of DNA replication upon RITA treatment. Replicating cells seemed more prone to entering RITA-induced apoptosis. Furthermore, the RITA-induced DNA damage response, which was not a secondary effect of apoptosis induction, was strongly attenuated in cells lacking p53 or Chk2. In conclusion, we identified Chk2 as an essential mediator of the cellular responses to RITA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22158418      PMCID: PMC3354051          DOI: 10.1038/cdd.2011.182

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  37 in total

1.  hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response.

Authors:  J S Lee; K M Collins; A L Brown; C H Lee; J H Chung
Journal:  Nature       Date:  2000-03-09       Impact factor: 49.962

2.  Surfing the p53 network.

Authors:  B Vogelstein; D Lane; A J Levine
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

3.  ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation.

Authors:  Shin'ichi Saito; Aaron A Goodarzi; Yuichiro Higashimoto; Yuka Noda; Susan P Lees-Miller; Ettore Appella; Carl W Anderson
Journal:  J Biol Chem       Date:  2002-03-01       Impact factor: 5.157

4.  Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription.

Authors:  Hiroyuki Takai; Kazuhito Naka; Yuki Okada; Miho Watanabe; Naoki Harada; Shin'ichi Saito; Carl W Anderson; Ettore Appella; Makoto Nakanishi; Hiroshi Suzuki; Kazuo Nagashima; Hirofumi Sawa; Kyoji Ikeda; Noboru Motoyama
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

5.  Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.

Authors:  J de Lange; L V Ly; K Lodder; M Verlaan-de Vries; A F A S Teunisse; M J Jager; A G Jochemsen
Journal:  Oncogene       Date:  2011-07-18       Impact factor: 9.867

6.  The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis.

Authors:  J Falck; N Mailand; R G Syljuåsen; J Bartek; J Lukas
Journal:  Nature       Date:  2001-04-12       Impact factor: 49.962

7.  ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1.

Authors:  H Zhao; H Piwnica-Worms
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

8.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.

Authors:  Q Liu; S Guntuku; X S Cui; S Matsuoka; D Cortez; K Tamai; G Luo; S Carattini-Rivera; F DeMayo; A Bradley; L A Donehower; S J Elledge
Journal:  Genes Dev       Date:  2000-06-15       Impact factor: 11.361

Review 9.  Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.

Authors:  Cynthia X Ma; James W Janetka; Helen Piwnica-Worms
Journal:  Trends Mol Med       Date:  2010-11-17       Impact factor: 11.951

10.  Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation.

Authors:  J Y Ahn; J K Schwarz; H Piwnica-Worms; C E Canman
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

View more
  13 in total

1.  Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining In Vivo Antitumor Efficacy.

Authors:  Brian D Peyser; Ann Hermone; Joseph M Salamoun; James C Burnett; Melinda G Hollingshead; Connor F McGrath; Rick Gussio; Peter Wipf
Journal:  Mol Cancer Ther       Date:  2019-07-24       Impact factor: 6.261

2.  Integrin α5β1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma.

Authors:  G Renner; H Janouskova; F Noulet; V Koenig; E Guerin; S Bär; J Nuesch; F Rechenmacher; S Neubauer; H Kessler; A-F Blandin; L Choulier; N Etienne-Selloum; M Lehmann; I Lelong-Rebel; S Martin; M Dontenwill
Journal:  Cell Death Differ       Date:  2015-10-16       Impact factor: 15.828

Review 3.  Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.

Authors:  Tiffany Devine; Mu-Shui Dai
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

4.  Gallotannin imposes S phase arrest in breast cancer cells and suppresses the growth of triple-negative tumors in vivo.

Authors:  Tiejun Zhao; Qiang Sun; Sonia V del Rincon; Amanda Lovato; Maud Marques; Michael Witcher
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

5.  The p53-reactivating small molecule RITA induces senescence in head and neck cancer cells.

Authors:  Hui-Ching Chuang; Liang Peng Yang; Alison L Fitzgerald; Abdullah Osman; Sang Hyeok Woo; Jeffrey N Myers; Heath D Skinner
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

6.  TRIM8 anti-proliferative action against chemo-resistant renal cell carcinoma.

Authors:  Mariano Francesco Caratozzolo; Alessio Valletti; Margherita Gigante; Italia Aiello; Francesca Mastropasqua; Flaviana Marzano; Pasquale Ditonno; Giuseppe Carrieri; Hélène Simonnet; Anna Maria D'Erchia; Elena Ranieri; Graziano Pesole; Elisabetta Sbisà; Apollonia Tullo
Journal:  Oncotarget       Date:  2014-09-15

7.  RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.

Authors:  Sylvanie Surget; Géraldine Descamps; Carole Brosseau; Vincent Normant; Sophie Maïga; Patricia Gomez-Bougie; Nadège Gouy-Colin; Catherine Godon; Marie C Béné; Philippe Moreau; Steven Le Gouill; Martine Amiot; Catherine Pellat-Deceunynck
Journal:  BMC Cancer       Date:  2014-06-14       Impact factor: 4.430

8.  Molecular dynamics of the full-length p53 monomer.

Authors:  Giovanni Chillemi; Pavel Davidovich; Marco D'Abramo; Tazhir Mametnabiev; Alexander Vasilievich Garabadzhiu; Alessandro Desideri; Gerry Melino
Journal:  Cell Cycle       Date:  2013-09-05       Impact factor: 4.534

9.  CRISPR-Cas9-based target validation for p53-reactivating model compounds.

Authors:  Michael Wanzel; Jonas B Vischedyk; Miriam P Gittler; Niklas Gremke; Julia R Seiz; Mirjam Hefter; Magdalena Noack; Rajkumar Savai; Marco Mernberger; Joël P Charles; Jean Schneikert; Anne Catherine Bretz; Andrea Nist; Thorsten Stiewe
Journal:  Nat Chem Biol       Date:  2015-11-23       Impact factor: 15.040

10.  Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation.

Authors:  Wei-Ling Chang; Lih-Ching Hsu; Wohn-Jenn Leu; Ching-Shih Chen; Jih-Hwa Guh
Journal:  Oncotarget       Date:  2015-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.